RLAY VS NVO Stock Comparison

Performance

RLAY
10/100

RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Technicals

RLAY
64/100

RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

RLAY
10/100

RLAY has missed earnings 8 times in the last 20 quarters.

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

RLAY
10/100

Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

Volatility

RLAY
53/100

RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

RLAY

"Analyst Price Targets" not found for RLAY

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

All score calculations are broken down here to help you make more informed investing decisions

Relay Therapeutics, Inc. Common Stock Summary

Nasdaq / RLAY

Healthcare

Biotechnology

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO

Healthcare

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Power up your portfolio